For a complete discussion of the assumptions, risks and uncertainties
related to our business, you are encouraged to review our filings with
Canadian securities regulatory authorities, including our 2007 Annual
Information Form filed on SEDAR at http://www.sedar.com. Historical filings
relating to the Company prior to the completion of the Company's March 23,
2006 corporate reorganization may be reviewed on SEDAR at
http://www.sedar.com under the SEDAR profile GVIC Communications Corp.
All forward-looking statements and information made herein are based on our current expectations as of the date hereof and we disclaim any intention or obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
Nventa Biopharmaceuticals Corp
Condensed Consolidated Statement of Operations
(Canadian dollars)(In thousands, except per share amounts)
Three Months Ended Twelve Months Ended
December 31, December 31,
2007 2006 2007 2006
and development revenue $156 $156 $621 $621
Research and development 1,549 1,587 6,596 7,351
Selling, general and
administrative 922 714 4,529 3,565
Corporate restructuring 30 - 844 -
2,501 2,301 11,969 1
|SOURCE Nventa Biopharmaceuticals Corporation|
Copyright©2008 PR Newswire.
All rights reserved